<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02301858</url>
  </required_header>
  <id_info>
    <org_study_id>SIV 9743</org_study_id>
    <nct_id>NCT02301858</nct_id>
  </id_info>
  <brief_title>Identification of Predictive and Prognostic Markers for Lung Cancer With Metastases</brief_title>
  <official_title>Identification of Predictive and Prognostic Markers for Lung Cancer With Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janna Berg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sykehuset i Vestfold HF</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project aims to compare the histopathological and molecular characteristics of tumour&#xD;
      tissue from metastases with similar analyses of the primary tumour in the lung, where it is&#xD;
      available.&#xD;
&#xD;
      The investigators will therefore perform analysis of blood samples if possible, to identify&#xD;
      predictive markers in blood samples.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators want to make genome analysis of tissue samples. This involves analysing the&#xD;
      RNA, DNA methylation, for example in cancer cells. This will provide information regarding&#xD;
      somatic changes in cancer cells, such as mutations. All of the investigators analysis will be&#xD;
      cancer-focused, with the goal of increasing understanding of the heterogeneity.&#xD;
&#xD;
      The investigators will therefore perform analysis of blood samples if possible, to identify&#xD;
      predictive markers in blood samples. This will then be the miRNA, RNA expression or protein&#xD;
      expression in blood samples.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparing histopathological and molecular characteristics of tumour tissue from metastases with the primary tumour in the lung</measure>
    <time_frame>5 years</time_frame>
    <description>We will do profiling of the mRNA (messenger ribonucleic acid) expression of microRNA and perform single nucleotide polymorphism analysis of cancer tissue and compare the expression using statistical methods such as SAM (Significance analysis and microarrays), PAM (Prediction analysis of microarrays). In addition, we wish to perform specific genetic analysis of cancer-related genes. These will be made with available methods like sequencing or TaqMan assays for specific mutations.&#xD;
Blood samples will be analysed by microarray methods for RNA and microRNA in addition to serum analysis of proteins.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Primary Tumor</condition>
  <condition>Metastases</condition>
  <arm_group>
    <arm_group_label>Study arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Genome analysis of tissue samples.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genome analysis of tissue samples.</intervention_name>
    <description>Genome analysis of tissue samples.</description>
    <arm_group_label>Study arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with metastasizing lung cancer where further treatment is still applicable.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Terminal patients or patients in a reduced general condition with EGOC 3-4, i.e.&#xD;
             patients who are confined to bed more than 50% of the day, with no clinical indication&#xD;
             to perform sampling of the tumor and metastases.&#xD;
&#xD;
          -  Patients where further cancer treatment is no longer applicable.&#xD;
&#xD;
          -  Patients with cognitive impairment.&#xD;
&#xD;
          -  Patients with inaccessible metastases where sampling may cause distress to the patient&#xD;
             and are at increased risk of complications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Janna Berg</last_name>
    <phone>+47 928 35 703</phone>
    <email>jannaberg1@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vestfold Hospital Trust</name>
      <address>
        <city>Tønsberg</city>
        <zip>3103</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janna Berg</last_name>
      <phone>4792835703</phone>
      <email>jannaberg1@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Åslaug Helland, PhD</last_name>
      <email>aslaug.helland@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 4, 2014</study_first_submitted>
  <study_first_submitted_qc>November 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2014</study_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sykehuset i Vestfold HF</investigator_affiliation>
    <investigator_full_name>Janna Berg</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>molecular pathology</keyword>
  <keyword>functional genomics</keyword>
  <keyword>lung cancer</keyword>
  <keyword>primary tumor</keyword>
  <keyword>metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

